Literature DB >> 9201178

The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria.

G S Whyte1, H F Savoia.   

Abstract

OBJECTIVE: To report the incidence rate of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV in Victorian repeat blood donors and to derive the residual risk of transmission of the viruses by screened blood transfusion.
DESIGN: The interval from the previous whole blood donation was extracted retrospectively from Victorian Red Cross Blood Bank records for each of the 358332 repeat donations given between March 1994 and December 1995. Records of repeat donors found positive for the viruses in this period were traced to the previous seronegative donation and accepted if screened by the same test. For each virus, the number of previous donations screened by the same test was calculated and the sum of all donation intervals used to derive the incidence of infection in the repeat donor population. Published intervals after infection (when a donation can be infective although seronegative) were used to calculate the risk of release of a seronegative unit which would be infective. PARTICIPANTS AND
SETTING: Homologous blood donors at the Red Cross Blood Bank of Victoria. MAIN OUTCOME MEASURES: Incidence rate of HBV, HCV and HIV in regular blood donors and risk of infective donations being seronegative.
RESULTS: The incidence of infection in repeat donors was: HBV: 1.67 per 100000 person-years; HCV: 1.89 per 100000 person-years; and HIV: 1.31 per 100000 person-years. The risk of a seronegative repeat donation being infective was: HBV: 2.71 per million donations (adjusted to 6.45 to account for viraemias which remain seronegative); HCV: 4.27 per million donations; and HIV: 0.79 per million donations.
CONCLUSION: The risk of transmitting HCV, HBV or HIV by repeat blood donors is low and compares favourably with overseas data. Repeat donors have an incidence rate of HIV and HBV comparable to that of the general population, but the incidence rate of HCV is lower for repeat donors than in the general population.

Entities:  

Mesh:

Year:  1997        PMID: 9201178     DOI: 10.5694/j.1326-5377.1997.tb123269.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  7 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  Desmopressin for minimising perioperative allogeneic blood transfusion.

Authors:  P A Carless; D A Henry; A J Moxey; D O'Connell; B McClelland; K M Henderson; K Sly; A Laupacis; D Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 3.  Cell salvage for minimising perioperative allogeneic blood transfusion.

Authors:  Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 4.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion.

Authors:  Paul A Carless; Fraser D Rubens; Danielle M Anthony; Dianne O'Connell; David A Henry
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

6.  Nucleic acid testing: Is it the only answer for safe Blood in India?

Authors:  N K Naidu; Z S Bharucha; Vandana Sonawane; Imran Ahmed
Journal:  Asian J Transfus Sci       Date:  2016 Jan-Jun

Review 7.  Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion.

Authors:  D A Henry; P A Carless; A J Moxey; D O'Connell; M A Forgie; P S Wells; D Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2002
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.